{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-403429","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2026-09-28T12:10:41+00:00","discovered_at":"2026-09-28T12:15:32.431096+00:00","generated_at":"2026-10-12T13:31:08.885791+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate Therapeutics receives $15.0M CIRM CLIN2 grant for Phase 2 RECLAIM-LN trial of FT819","bullets":["CIRM awarded Fate a $15.0 million CLIN2 grant on Sept 25, 2026 to support RECLAIM-LN, the Phase 2 potentially registrational trial of FT819.","RECLAIM-LN (FT819-201; NCT07570862) plans to enroll approximately 53 refractory SLE patients with lupus nephritis; primary endpoint is complete renal response at Week 26.","FT819 is an off-the-shelf iPSC-derived CAR T-cell therapy; Phase 1 data showed favorable safety and clinically meaningful SLEDAI-2K and UPCr improvements.","FT819 holds FDA RMAT designation and was selected for the FDA's CMC Development and Readiness Pilot (CDRP) program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-403429","json":"https://secwatch.observer/filing/0001193125-26-403429.json","markdown":"https://secwatch.observer/filing/0001193125-26-403429.md","text":"https://secwatch.observer/filing/0001193125-26-403429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/0001193125-26-403429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/fate-20260925.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:31:08.885791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}